Arcturus Therapeutics
ARCT
148 hedge funds and large institutions have $453M invested in Arcturus Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 55 increasing their positions, 47 reducing their positions, and 31 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 47
1.3% more ownership
Funds ownership: 97.1% → 98.39% (+1.3%)
6% more capital inflows, than outflows
Capital inflows: $53.1M | Capital outflows: $50M
1% less call options, than puts
Call options by funds: $2.94M | Put options by funds: $2.98M
10% less funds holding
Funds holding: 164 → 148 (-16)
48% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.3M |
| 2 |
Schonfeld Strategic Advisors
New York
|
+$9.03M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$5.57M |
| 4 |
Morgan Stanley
New York
|
+$5.11M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$4.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.48M |
| 2 |
Nikko Asset Management Americas
New York
|
-$4.71M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$3.97M |
| 4 |
Royce & Associates
New York
|
-$3.62M |
| 5 |
ARK Investment Management
St. Petersburg,
Florida
|
-$3.15M |
ARCT Hedge Fund Activity: Q4 2024 in Review
148 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2024, worth a combined $453M — down 26% from $609M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ARCT and 16 opened new positions — a net loss of 15 holders — while 47 trimmed existing stakes and 55 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $10.3M. The largest seller was Millennium Management, exiting entirely with an estimated $5.48M sold.
- 148 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2024, down from 164 in Q3 2024.
- Funds reported $453M of Arcturus Therapeutics stock for Q4 2024, down 26% quarter-over-quarter.
- 16 funds opened new Arcturus Therapeutics positions in Q4 2024 and 31 closed out, a net change of -15 holders.
- The largest Arcturus Therapeutics buyer in Q4 2024 was Balyasny Asset Management, an estimated $10.3M added.
- The largest Arcturus Therapeutics seller in Q4 2024 was Millennium Management, an estimated $5.48M sold.
Based on aggregated 13F filings for Q4 2024.